120 related articles for article (PubMed ID: 11170141)
1. Volume-weighted mean nuclear volume predicts tumor biology of clinically organ-confined prostate cancer.
Arai Y; Okubo K; Terada N; Matsuta Y; Egawa S; Kuwao S; Ogura K
Prostate; 2001 Feb; 46(2):134-41. PubMed ID: 11170141
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification after radical prostatectomy in men with pathologically organ-confined prostate cancer using volume-weighted mean nuclear volume.
Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
Prostate; 2005 Aug; 64(3):217-23. PubMed ID: 15712275
[TBL] [Abstract][Full Text] [Related]
3. Impact of volume weighted mean nuclear volume on outcomes following salvage radiation therapy after radical prostatectomy.
Matsui Y; Ichioka K; Terada N; Yoshimura K; Terai A; Dodo Y; Arai Y
J Urol; 2004 Feb; 171(2 Pt 1):687-91. PubMed ID: 14713787
[TBL] [Abstract][Full Text] [Related]
4. The role of volume-weighted mean nuclear volume in predicting disease outcome in patients with prostate cancer treated with radical prostatectomy.
Fujikawa K; Itoh T; Nishio Y; Miyakawa M; Sasaki M
APMIS; 1999 Aug; 107(8):773-8. PubMed ID: 10515128
[TBL] [Abstract][Full Text] [Related]
5. The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting.
Arai Y; Egawa S; Kuwao S; Ogura K; Baba S
BJU Int; 2001 Dec; 88(9):909-14. PubMed ID: 11851612
[TBL] [Abstract][Full Text] [Related]
6. The role of volume-weighted mean nuclear volume in predicting disease outcome in patients with stage M1 prostate cancer.
Fujikawa K; Aoyama T; Itoh T; Nishio Y; Miyakawa M; Sasaki M
APMIS; 1999 Apr; 107(4):395-400. PubMed ID: 10230693
[TBL] [Abstract][Full Text] [Related]
7. Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume.
Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Takeuchi H
J Urol; 2000 Nov; 164(5):1587-90. PubMed ID: 11025710
[TBL] [Abstract][Full Text] [Related]
8. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
10. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
11. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
12. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
13. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
14. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer.
Bianco FJ; Wood DP; Cher ML; Powell IJ; Souza JW; Pontes JE
Clin Prostate Cancer; 2003 Mar; 1(4):242-7. PubMed ID: 15040883
[TBL] [Abstract][Full Text] [Related]
15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
16. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
17. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
18. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
19. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
20. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
